BioProcess International’s Post

Learn more about the standard in AAV manufacturing with our latest article

Cell culture automation is revolutionizing drug development. 🌟 The transition from traditional 2D models to 3D cell culture has been a game changer, significantly boosting predictive responses to anti-cancer compounds. However, manual 3D workflows are error-prone and labor-intensive. Enter the CellXpress.ai Automated Cell Culture System by Molecular Devices UK, which streamlines the entire process, from cell plating to imaging and analysis. Having used the automated system, the efficiency and standardization it brings to high-throughput drug screening are remarkable. For example, treating colorectal cancer spheroids with anti-cancer compounds like staurosporine led to observable and measurable decreases in cell viability using luminescent read-outs. Automation isn’t just about speed—it’s about confidence in drug screening readouts and deeper insights for precision medicine. 🧬🔬 How have automated systems improved your workflows? Share your experiences below! 👇 #drugdevelopment #cellculture #biotechnology #automation #cancerresearch #precisionmedicine

Phialogics is a preclinical biotech company specialized in engineering next-generation biologics to rebalance the immune response in acute and chronic inflammation. Phialogics concept is based on the targeted modification of immunoglobulin receptor domains (IgVs) to modulate immune response in inflammatory diseases. IgV mediated receptor-ligand interaction represents a significant source of novel biologics. Phialogics lead molecules replicate endogenous protein-protein interactions to efficiently modulate the function of their target receptor. So far, only this unique platform technology can achieve such a high level of precision. Meet Phialogics AG @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

𝐇𝐚𝐫𝐧𝐞𝐬𝐬𝐢𝐧𝐠 𝐭𝐡𝐞 𝐏𝐨𝐰𝐞𝐫 𝐨𝐟 𝐈𝐦𝐦𝐮𝐧𝐞 𝐂𝐞𝐥𝐥𝐬: 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐟𝐨𝐫 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐁𝐞𝐧𝐞𝐟𝐢𝐭 The immune cell engineering market refers to the dynamic and rapidly evolving field within biotechnology that focuses on the manipulation and enhancement of immune cells to treat various diseases, particularly cancer. This innovative approach involves modifying the genetic makeup or functional properties of immune cells, such as T cells, to bolster their ability to recognize and eliminate targeted cells, including cancerous ones. With the advent of cutting-edge technologies like CRISPR-Cas9 and advancements in cell therapy, the immune cell engineering market holds great promise for developing personalized and highly effective treatments, ushering in a new era in the realm of immunotherapy. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗦𝗮𝗺𝗽𝗹𝗲:https://lnkd.in/dFnVXRh5 𝐏𝐫𝐨𝐦𝐢𝐧𝐞𝐧𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐈𝐦𝐦𝐮𝐧𝐞 𝐂𝐞𝐥𝐥 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 Thermo Fisher Scientific Merck KGaA, Darmstadt, Germany Danaher Corporation Lonza Miltenyi Biotec Takara Bio USA, Inc. FUJIFILM Irvine Scientific Agilent Technologies Bio-Techne Bio-Rad Laboratories Becton Dickenson Charles River Laboratories Creative Bioarray Sartorius Novogene America AGC Biologics #ImmuneEngineering #CARTCells #TCRTherapy #ImmuneTherapy #CancerImmunotherapy #GeneEditing #Immunomodulation #CellTherapy #ImmunotherapyResearch #CellularEngineering

🔬 Exciting Publication -->Apricell Biotechnology -->3-in-1 Plate! 🔬 Researchers utilized the 3D #tumoroid culture plate from Apricell Biotechnology Inc. to create a human-mimicked #Glioblastoma tumor model. This study aimed to evaluate the impact of #localized combination #drugdelivery on the #viability and invasive behavior of tumor #spheroids within a bio-mimicked #extracellularmatrix of the tumor site. https://lnkd.in/e74gjkcA 💡At Apricell Biotechnology Inc., we are committed to advancing scientific innovation and revolutionizing the way researchers conduct cell-based assays. 3-in-1 Plate offers a cutting-edge solution for creating physiologically relevant #3dcellculture models, facilitating #therapeutic screening, and accelerating #drugdiscovery efforts. We are proud to contribute to advancing cancer research and look forward to seeing the impact of our 3-in-1 plate on the future of #invitro human-mimicked #cancer models. For more information on our revolutionary range of products, including the 3-in-1 Plate, please visit our website or contact us directly at info@apricell.com. Let us work together to explore new possibilities in 3D cell culture and therapeutic discovery! #Microfluidics #organoids #DrugDiscovery #BiomedicalResearch #Innovation #Science #Publication #ResearchAdvancement

🔬 Biomarkers Market: Driving Precision Medicine & Drug Development 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐯𝐞 𝐏𝐃𝐅: https://lnkd.in/dMa-RfF8 The global biomarkers market is experiencing rapid growth, fueled by advances in: - Products: Consumables, software - Types: Safety, efficacy biomarkers - Technologies: NGS, PCR, mass spectrometry - Applications: Diagnostics, clinical trials Key growth areas: - Cancer & infectious disease research - Personalized medicine - Drug discovery & development As healthcare moves towards targeted therapies, biomarkers are becoming essential tools for improving patient outcomes and accelerating pharmaceutical innovation. What biomarker applications are you most excited about? Share your thoughts! #Biomarkers #PrecisionMedicine #DrugDiscovery #HealthcareInnovation

Exosomes have the potential to be the next major advancement in therapeutics. The field of exosome-based treatments is growing rapidly and may revolutionize areas like drug delivery, regenerative medicine, and diagnostics. Their function is entirely influenced by the originating donor cell, with the capacity to have either positive or negative effects. In regenerative medicine, particularly in cultured cell therapies, exosomes show promise as a potential disease-modifying approach for autoimmune conditions. However, it's important to emphasize that exosome therapies are not yet FDA-approved and should remain confined to research or FDA Biologics License Applications. Exosome-based therapies present a compelling alternative to CAR-T treatments. Early research suggests that exosomes derived from CAR-T cells could address current challenges by being engineered for therapeutic benefits while retaining CAR-T cells' targeted cancer-fighting abilities. Emerging companies like Direct Biologics (ExoFlo), Capricor Therapeutics, Inc. (CAP-1002), Aegle Therapeutics (AGLE-102), EV Therapeutics (EV-101), INNOVEX THERAPEUTICS SL (ExoCoVac), and ILIAS Biologics Inc. (ILB 202) are exploring exosome therapies. Additionally, companies such as Aruna Bio, Inc., EXO Biologics , ReNeuron Group Plc, and Coya Therapeutics, Inc., are actively involved in this space. The upcoming introduction of these therapies is expected to significantly impact the therapeutics market. With ongoing research and clinical trials, exosome therapies are well-positioned to transform personalized medicine and create new opportunities for treating various diseases. Read more @ https://lnkd.in/dFJfDzXK

🌟 Join Us for the Donor Selection and Cell Source Summit! 🌟 The cell therapy field is at the forefront of a revolution, especially in developing treatments for autoimmune patients. With over 150+ clinical trials currently underway and recent FDA approvals for allogeneic cell products, the momentum in this space is undeniable. 🚀 As the allogeneic cell therapy field continues to mature, the focus is now shifting to one of the most critical aspects of these therapies—the cell donors. We’re excited to announce that this year's summit will address the core questions and challenges surrounding donor characterization, with a special emphasis on: 🔍 Donor Variability 🎯 Donor Selection 🔄 Donor Retention / Consistent Donor Supply 📈 Scalability / Safety & Efficacy We've collaborated with leading companies in the Cell Therapy space, including Sana Biotech, Poseida Therapeutics, and BMS, to craft an agenda that will propel this emerging field even further. Don't miss out on this opportunity to be part of the conversation that's shaping the future of cell therapy! #CellTherapy #DonorSelection #AllogeneicTherapy #Biotech #HealthcareInnovation The full agenda can be viewed here: https://lnkd.in/eJRRzzhU

Indian Institute of Technology, Madras, Indian Institute of Technology, Mandi 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵𝗲𝗿𝘀 𝗲𝗻𝗴𝗶𝗻𝗲𝗲𝗿 𝑵𝒐𝒕𝒉𝒂𝒑𝒐𝒅𝒚𝒕𝒆𝒔 𝒏𝒊𝒎𝒎𝒐𝒏𝒊𝒂𝒏𝒂 𝗽𝗹𝗮𝗻𝘁 𝗰𝗲𝗹𝗹𝘀 𝘁𝗼 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 𝗖𝗮𝗺𝗽𝘁𝗼𝘁𝗵𝗲𝗰𝗶𝗻 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻, 𝘂𝘀𝗲𝗱 𝗶𝗻 𝗰𝗮𝗻𝗰𝗲𝗿 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 Camptothecin (CPT) is an important anti-cancer drug lead molecule for high-value drugs like Topotecan and Irinotecan. The researchers from the Plant Cell Technology Lab of IIT Madras have developed a genome-scale metabolic model for 𝑵𝒐𝒕𝒉𝒂𝒑𝒐𝒅𝒚𝒕𝒆𝒔 𝒏𝒊𝒎𝒎𝒐𝒏𝒊𝒂𝒏𝒂 plant cells using computational tools. 𝐒𝐨𝐮𝐫𝐜𝐞: The Economic Times #camptothecin #phytochemicals #pharmacognosy #pharmaceuticals #anticancer #iitmadras #iitmandi #learnwithirudhayam

New in Cell Reports Medicine: UCLA scientists led by Dr. Arjun Deb have developed a monoclonal antibody therapy that targets ENPP1, a protein linked to increased inflammation and scar tissue formation after heart attacks. In preclinical studies, a single dose of this therapy significantly improved heart function and reduced the risk of heart failure. “Despite the prevalence of heart attacks, therapeutic options have stagnated over the last few decades,” said Deb. "Based on this therapy's effect on heart repair, this could represent a new class of tissue repair-enhancing drugs.” ➡️ https://ucla.in/3YBcz9D 📷: ENPP1 is expressed in the region of scarring after injury to the heart. Cardiac muscle shown in red and ENPP1 in green demonstrates expression of ENPP1 in the region of scar formation. | Credit: Arjun Deb Lab/UCLA